Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice

Clinical and Vaccine Immunology

Volumn 18, Issue 5, 2011, Pages 717-723

  Wozniak, Karen L ^a   Young, Mattie L ^a   Wormley Jr , Floyd L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CRYPTOCOCCUS NEOFORMANS VACCINE; FUNGUS VACCINE; GAMMA INTERFERON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; FUNGAL STRAIN; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PULMONARY CRYPTOCOCCOSIS; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; LUNG DISEASES, FUNGAL; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 79955735788     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00036-11     Document Type: Article

References (40)

1. Bingaman, A. W., et al. 2005. Novel phenotypes and migratory properties distinguish memory CD4 T cell subsets in lymphoid and lung tissue. Eur. J. Immunol. 35:3173-3186.
2. Bozzette, S. A., et al. 1991. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N. Engl. J. Med. 324:580-584.
3. Chuck, S. L., and M. A. Sande. 1989. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N. Engl. J. Med. 321:794-799.
4. Collins, V. P., A. Gellhorn, and J. R. Trimble. 1951. The coincidence of cryptococcosis and disease of the reticulo-endothelial and lymphatic systems. Cancer 4:883-889.
5. Cutler, J. E., G. S. Deepe, Jr., and B. S. Klein. 2007. Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 5:13-28.
6. de Bastos Ascencço Soares, R., F. J. Gomez, C. M. de Almeida Soares, and G. S. Deepe, Jr. 2008. Vaccination with heat shock protein 60 induces a protective immune response against experimental Paracoccidioides brasiliensis pulmonary infection. Infect. Immun. 76:4214-4221.
7. Deepe, G. S., Jr., and R. S. Gibbons. 2002. Cellular and molecular regulation of vaccination with heat shock protein 60 from Histoplasma capsulatum. Infect. Immun. 70:3759-3767.
8. Diamond, R. D., and J. E. Bennett. 1974. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann. Intern. Med. 80:176-181.
9. Dismukes, W. E. 1988. Cryptococcal meningitis in patients with AIDS. J. Infect. Dis. 157:624-628.
10. Duperval, R., P. E. Hermans, N. S. Brewer, and G. D. Roberts. 1977. Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract. Chest 72:13-19.
11. Eng, R. H., E. Bishburg, S. M. Smith, and R. Kapila. 1986. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am. J. Med. 81:19-23.
12. Gal, A. A., M. N. Koss, J. Hawkins, S. Evans, and H. Einstein. 1986. The pathology of pulmonary cryptococcal infections in the acquired immunode- ficiency syndrome. Arch. Pathol. Lab. Med. 110:502-507.
13. Gendel, B. R., M. Ende, and S. L. Norman. 1950. Cryptococcosis; a review with special reference to apparent association with Hodgkin's disease. Am. J. Med. 9:343-355.
14. Goldstein, E., and O. N. Rambo. 1962. Cryptococcal infection following steroid therapy. Ann. Intern. Med. 56:114-120.
15. Herring, A. C., J. Lee, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2002. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect. Immun. 70:2959-2964.
16. Huffnagle, G. B., and M. F. Lipscomb. 1998. Cells and cytokines in pulmonary cryptococcosis. Res. Immunol. 149:387-396. (Discussion, 149:512-514.)
17. + T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55:35-42.
18. Huffnagle, G. B., et al. 1996. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J. Immunol. 157:4529-4536. (Pubitemid 126449374)
19. Husain, S., M. M. Wagener, and N. Singh. 2001. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg. Infect. Dis. 7:375-381.
20. Keye, J. D., Jr., and W. E. Magee. 1956. Fungal diseases in a general hospital; a study of 88 patients. Am. J. Clin. Pathol. 26:1235-1253.
21. Kovacs, J. A., et al. 1985. Cryptococcosis in the acquired immunodeficiency syndrome. Ann. Intern. Med. 103:533-538.
22. Lewis, J. L., and S. Rabinovich. 1972. The wide spectrum of cryptococcal infections. Am. J. Med. 53:315-322.
23. Lindell, D. M., M. N. Ballinger, R. A. McDonald, G. B. Toews, and G. B. Huffnagle. 2006. Immunologic homeostasis during infection: coexistence of strong pulmonary cell-mediated immunity to secondary Cryptococcus neoformans infection while the primary infection still persists at low levels in the lungs. J. Immunol. 177:4652-4661.
24. + T cells during Cryptococcus neoformans infection. J. Immunol. 174:7920-7928.
25. Marr, K. J., et al. 2009. Cryptococcus neoformans directly stimulates perforin production and rearms NK cells for enhanced anticryptococcal microbicidal activity. Infect. Immun. 77:2436-2446.
26. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
27. Moretta, A., et al. 1991. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta. J. Exp. Med. 174:1393-1398.
28. Park, B. J., et al. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23:525-530.
29. Román, E., et al. 2002. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J. Exp. Med. 196:957-968.
30. Saag, M. S., et al. 2000. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30:710-718.
31. Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745-763.
32. Sancho, D., M. Gomez, and F. Sanchez-Madrid. 2005. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 26:136-140. (Pubitemid 40312520)
33. Saville, S. P., A. L. Lazzell, A. K. Chaturvedi, C. Monteagudo, and J. L. Lopez-Ribot. 2008. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect. Immun. 76:97-102.
34. van der Horst, C. M., et al. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337:15-21.
35. Vibhagool, A., et al. 2003. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin. Infect. Dis. 36:1329-1331.
36. Vivier, E., et al. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331:44-49.
37. Wormley, F. L., Jr, J. R. Perfect, C. Steele, and G. M. Cox. 2007. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect. Immun. 75:1453-1462.
38. Wozniak, K. L., et al. 2009. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One 4:e6854.
39. + T cells: implications for vaccine development in immune-deficient hosts. J. Exp. Med. 197:1405-1416.
40. Wüthrich, M., H. I. Filutowicz, T. Warner, and B. S. Klein. 2002. Requisite elements in vaccine immunity to Blastomyces dermatitidis: plasticity uncovers vaccine potential in immune-deficient hosts. J. Immunol. 169:6969-6976.